Neos Therapeutics (NASDAQ:NEOS) issued its earnings results on Friday. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.03), MarketWatch Earnings reports. Neos Therapeutics had a negative return on equity of 586.25% and a negative net margin of 164.40%. The business had revenue of $12.50 million for the quarter, compared to the consensus estimate of $14.80 million.
Shares of NASDAQ:NEOS traded up $0.01 during trading on Friday, reaching $2.59. The stock had a trading volume of 651,079 shares, compared to its average volume of 621,268. Neos Therapeutics has a one year low of $2.27 and a one year high of $11.69. The stock has a market capitalization of $83.38 million, a P/E ratio of -0.97 and a beta of 0.44.
NEOS has been the topic of several recent research reports. Wells Fargo & Co dropped their target price on shares of Neos Therapeutics from $14.00 to $11.00 and set a “buy” rating on the stock in a report on Thursday, August 9th. Cantor Fitzgerald reiterated a “buy” rating and set a $20.00 target price on shares of Neos Therapeutics in a report on Wednesday, August 8th. ValuEngine upgraded shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, September 24th. Finally, Zacks Investment Research upgraded shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 11th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Neos Therapeutics currently has a consensus rating of “Hold” and an average price target of $15.50.
In other news, Director Alan L. Heller purchased 43,478 shares of the stock in a transaction dated Thursday, November 8th. The shares were acquired at an average cost of $2.30 per share, for a total transaction of $99,999.40. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 5.40% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION WARNING: This news story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/11/10/neos-therapeutics-neos-issues-quarterly-earnings-results.html.
About Neos Therapeutics
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.
Featured Story: Penny Stocks
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.